Home / Share Price Target / Gls
Glenmark Life Sciences Share Price Target 2024, 2025, 2026 to 2039 With Charts
Glenmark Life Sciences Limited | |||
 | Symbol: GLS | ||
| Price: ₹1,082.58 | |||
| Exchange: NSE | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Glenmark Life Sciences Brief Company Overview
- 1.1: Glenmark Life Sciences Limited: A Leader in Active Pharmaceutical Ingredients
- 1.2: Glenmark Life Sciences Financial Performance
- 1.2.1: Is Glenmark Life Sciences A Good Buy For Long Term?
- 2: Approach 1: Technical Analysis Paired With Price Action
- 2.1: Glenmark Life Sciences Share Price Target For 2024
- 2.1.1: Glenmark Life Sciences Share Price Target Table For 2024
- 2.1.2: Summary: Glenmark Life Sciences Share Price Prediction For 2024
- 2.2: Glenmark Life Sciences Share Price Target For 2025
- 2.2.1: Glenmark Life Sciences Share Price Target Table For 2025
- 2.2.2: Summary: Glenmark Life Sciences Share Price Prediction For 2025
- 3: Approach 2: Machine Learning By Studying Historical Prices
- 3.1: Glenmark Life Sciences Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039
- 3.2: Glenmark Life Sciences Share Price Target Table From 2024, 2025, 2026 to 2039
- 4: Glenmark Life Sciences Past Performance
Glenmark Life Sciences Brief Company Overview
Glenmark Life Sciences Limited: A Leader in Active Pharmaceutical Ingredients
Incorporated in 2011, Glenmark Life Sciences Limited is a renowned player in the pharmaceutical industry. The company specializes in developing, manufacturing, and supplying non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas.
Glenmark Life Sciences
- Key Products: Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, Cilostazol, Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, Lacosamide, Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, Linagliptin, Etoricoxib, Lornoxicam, Zolmitriptan, Frovatriptan, Olaparib, Palbociclib, Enzalutamide, Ruxolitinib, Atovaquone, Adapalene
- Services: Contract development and manufacturing services
- Market Presence: Exports products to Europe, North America, Latin America, Japan, and internationally
Glenmark Life Sciences is committed to providing high-quality products and services, meeting the evolving needs of the pharmaceutical industry.
Advertisement
Glenmark Life Sciences Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 13,430.84 Crore | Market valuation of Glenmark Life Sciences's shares. |
| Revenue (TTM) | 2,204.89 Crore | Total revenue generated by Glenmark Life Sciences over the past twelve months. |
| Net Income (TTM) | +423.5 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 23.52% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 19.2% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) | -14.9% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) | -19.7% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio | 0.62 | Company's total debt divided by total shareholder equity. |
| Total Debt | 15.97 Crore | Sum of Glenmark Life Sciences's current & long-term financial obligations. |
| Total Cash | 446.29 Crore | Total amount of liquid funds available to Glenmark Life Sciences. |
| Beta | 0.16 | Beta is less than 1 indicating that the Glenmark Life Sciences's price is less volatile than the market. |
Is Glenmark Life Sciences A Good Buy For Long Term?
Glenmark Life Sciences, a mid-cap stock with a market capitalization of ₹13,088.97 crore, shows mixed signals for long-term investment. While its ₹423.5 crore net profit (19.2% margin) on ₹2,204.89 crore revenue in the last 12 months is positive, a -19.7% YoY earnings decline and -14.9% QoQ revenue drop raise concerns. Impressive past returns (73.22% in 12 months, 64.76% YTD) are counterbalanced by lack of data for the past three and five years. Low debt (₹15.97 crore) and substantial cash (₹446.29 crore) are favorable. Overall, it's an average buy, requiring further due diligence before committing to a long-term strategy.
To predict the Glenmark Life Sciences's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Glenmark Life Sciences Share Price Target For 2024
The line chart displays the monthly closing prices of Glenmark Life Sciences with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Glenmark Life Sciences shares in 2024, see the table below.
Advertisement
Glenmark Life Sciences Share Price Target Table For 2024
| Glenmark Life Sciences's Levels | Value | Reason/Importance |
|---|---|---|
| 2024 Target 3 | 1114.94 (+2.98%) | Price Action: 06 Nov 2024 High |
| 2024 Target 2 | 1103.34 (+1.91%) | Price Action: 11 Nov 2024 High |
| 2024 Target 1 | 1091.94 (+0.86%) | Price Action: 24 Oct 2024 High |
| Current Price | 1082.59 | Glenmark Life Sciences's 1 share price as of Thu 14 Nov 2024 |
| Stop Loss 1 | 1078.32 (-0.4%) | Fibonacci Retracement Level 38.2% |
| Stop Loss 2 | 1065.44 (-1.59%) | Price Action: 06 Nov 2024 Low |
| Stop Loss 3 | 1053.19 (-2.72%) | Price Action: 05 Nov 2024 Low |
Summary: Glenmark Life Sciences Share Price Prediction For 2024
In summary, Glenmark Life Sciences has surged by ₹425.54, achieving a notable +64.77% increase from 1st January 2024 to 14 Nov 2024. Our analysis of Glenmark Life Sciences for 2024 predicts an additional rise of 0.86% to 2.98% by the end of 2024 with three potential targets T1: 1091.94, T2: 1103.34, T3: 1114.94. Stop Loss at SL1: 1078.32, SL2: 1065.44, SL3: 1053.19.
Glenmark Life Sciences has a 52-week high of ₹1335.09, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹620.20, a critical support level - think of this as a safety net where the price might stop falling.
After looking at 2024's share price prediction, let's now check what 2025 might hold for Glenmark Life Sciences.
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Glenmark Life Sciences Share Price Target For 2025
The line chart displays the monthly closing prices of Glenmark Life Sciences with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Glenmark Life Sciences shares in 2025, see the table below.
Advertisement
Glenmark Life Sciences Share Price Target Table For 2025
| Glenmark Life Sciences's Levels | Value | Reason/Importance |
|---|---|---|
| 2025 Target 3 | 1450.88 (+34.01%) | Fibonacci Extension Level 171.8% |
| 2025 Target 2 | 1411.92 (+30.42%) | Price Action: Chart |
| 2025 Target 1 | 1397.94 (+29.12%) | Custom Fibonacci Extension Lvl 64.9% |
| Current Price | 1082.59 | Glenmark Life Sciences's 1 share price as of Thu 14 Nov 2024 |
| Stop Loss 1 | 1006.90 (-7%) | Price Action: Aug 2024 Low |
| Stop Loss 2 | 991.45 (-8.42%) | Price Action: 28 Oct 2024 High |
| Stop Loss 3 | 976.25 (-9.83%) | Price Action: 29 Oct 2024 Low |
Summary: Glenmark Life Sciences Share Price Prediction For 2025
In summary, Glenmark Life Sciences has surged by ₹425.54, achieving a notable +64.77% increase from 1st January 2024 to 14 Nov 2024. Our analysis of Glenmark Life Sciences for 2025 predicts an additional rise of 29.12% to 34.01% by the end of 2025 with three potential targets T1: 1397.94, T2: 1411.92, T3: 1450.88. Stop Loss at SL1: 1006.90, SL2: 991.45, SL3: 976.25.
Glenmark Life Sciences has a All-Time high of ₹1335.09, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹620.20, a critical support level - think of this as a safety net where the price might stop falling.
After looking at 2024's and 2025's share price prediction, you might wonder what are short term targets for Glenmark Life Sciences, we have created a specific page for that check here: Glenmark Life Sciences Share Price Target For Tomorrow & Next Week
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Glenmark Life Sciences Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039
This chart presents a detailed projection of Glenmark Life Sciences share price predictions from 2024, 2025, 2026 to 2039. This share price Prediction represents a CAGR of 14.15% over the next 15 years.
For complete year by year Glenmark Life Sciences long term share price target from 2024, 2025 to 2039 check the below table.
Glenmark Life Sciences Share Price Target Table From 2024, 2025, 2026 to 2039
| Year | Glenmark Life Sciences Target | YoY Change % |
|---|---|---|
| 2024 | ₹1,082.58 | [Current Price] |
| 2024 | ₹1,153.93 | 6.58% |
| 2025 | ₹1,606.92 | 39.25% |
| 2026 | ₹2,030.93 | 26.38% |
| 2027 | ₹2,358.42 | 16.12% |
| 2028 | ₹2,905.1 | 23.17% |
| 2029 | ₹3,245.05 | 11.7% |
| 2030 | ₹3,744.28 | 15.38% |
| 2031 | ₹4,164.66 | 11.22% |
| 2032 | ₹4,405.97 | 5.79% |
| 2033 | ₹5,054.12 | 14.71% |
| 2034 | ₹5,336.17 | 5.58% |
| 2035 | ₹5,881.65 | 10.22% |
| 2036 | ₹6,298.39 | 7.08% |
| 2037 | ₹6,453.54 | 2.46% |
| 2038 | ₹7,203.14 | 11.61% |
| 2039 | ₹7,356.46 | 2.12% |
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Glenmark Life Sciences Past Performance
- In 2021, Glenmark Life Sciences opening price was ₹696.7
- As of Thu 14 Nov 2024 the price stands at ₹1,082.58.
- This represents a Compound Annual Growth Rate (CAGR) of 11.65%.
- In 3 years, an investment of 10,000 would have become ₹15,538.82.
As we wrap up, we hope you like our study on Glenmark Life Sciences share price predictions, please kindly note that these forecasts are based on technical analysis, past trends, and machine learning models. They are for educational purposes only, not investment advice.
Show Methodology We Use
Methodology Behind the Prediction
The share price predictions present on our site are derived from a robust model that incorporates multiple economic indicators, technical indicators, company performance metrics, and industry-specific factors.
We have historical share price data of all stocks for which we present targets, so we analyse historical trends from those past data and overlay them with projected market conditions to estimate future share prices of a stock.
- Glenmark Life Sciences Share Price History
- Glenmark Life Sciences Price Target Tomorrow
- Glenmark Life Sciences Dividend History
Disclaimer: Information is provided 'as is' and solely for informational and educational purposes, not for trading purposes or advice. We highly recommend to do your own research before making any investment.
